Evidence map›Paper›PMID 32524634›Full record

ArticleJournal of surgical oncology2020

Conditional survival analysis of hepatocellular carcinoma.

Mihir M Shah, Benjamin I Meyer, Kevin Rhee, Rachel E NeMoyer, Yong Lin, Ching-Wei D Tzeng, Salma K Jabbour, Timothy J Kennedy, John L Nosher, David A Kooby and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Mihir M ShahDivision of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.ORCID http://orcid.org/0000-0002-8228-2683
Benjamin I MeyerDivision of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.ORCID http://orcid.org/0000-0002-0970-5854
Kevin RheeDepartment of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
Rachel E NeMoyerDepartment of Surgery, Rutgers Robertwood Johnson Medical School, New Brunswick, New Jersey.
Yong LinDepartment of Biostatistics, Rutgers School of Public Health, Piscataway, New Jersey.
Ching-Wei D TzengDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Salma K JabbourDepartment of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
Timothy J KennedyDepartment of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
John L NosherDepartment of Radiology, Rutgers Robertwood Johnson Medical School, New Brunswick, New Jersey.
David A KoobyDivision of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.ORCID http://orcid.org/0000-0001-8694-0455
Shishir K MaithelDivision of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
Darren R CarpizoDivision of Surgical Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, New York.
Rutgers, The State University of New Jersey · USEmory University · USThe University of Texas MD Anderson Cancer Center · USUniversity of Rochester · US

Funding

Development of Zinc Metallochaperones as Mutant p53 Targeted Anti-cancerDrugsR01CA200800 · NCI · UNIVERSITY OF ROCHESTER · PI CARPIZO, DARREN RICHARD · 2016 to 2020
$1.9M
NCI NIH HHS R01 CA200800NIH HHS R01 CA20080
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide with an approximate 5-year survival of greater than 50% in patients after surgical resection. Survival estimates have limited utility for patients who have survived several years after initial treatment. We analyzed how conditional survival (CS) after curative-intent surgery for HCC predicts survival estimates over time.

methodsNCDB (2004-2014) was queried for patients undergoing definitive surgical resection for HCC. Cumulative overall survival (OS) was calculated using the Kaplan-Meier method, and CS at x years after diagnosis was calculated as CS

resultsThe final analysis encompassed 11 357 patients. Age, negative margin status, grade severity and radiation before surgery were statistically significant predictors of cumulative overall conditional survival (P ≤ .0001). Overall unconditional 5-year survival was 65.7%, but CS estimates were higher. A patient who has already survived 3 years has an additional 2-year, or 5-year CS, estimate of 86.96%.

conclusionSurvival estimates following hepatic resection in HCC patients change according to survival time accrued since surgery. CS estimates are improved relative to unconditional OS. The impact of different variables influencing OS is likewise nonlinear over the course of time after surgery.

Indexed as

cirrhosisconditional survivalhepatocellular carcinomaliver cancerliver surgery

Identifiers

PMID32524634
PMCPMC8565605
OpenAlexW3033445219

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.